Zogenix Inc

Zogenix — Investor Presentation (September 2016)

21 slides from Zogenix's investor presentation, Sep 27, 2016

  1. Slide 1: Company Presentation September 2016

    Exhibit 99.1 NASDAQ: ZGNX Company Presentation S e p t e m b e r 2 0 1 6

  2. Slide 2: Forward Looking Statements

    Forward “will,” statements of exclusivity marketed the conduct federal, rights described Zogenix care development, for “potential” for state its undertakes Looking RELDAY; drug intreatment regarding: clinical and the and products. potential company’s local testing, Statement and trials, no Zogenix o

  3. Slide 3: Late Stage Development Opportunities in CNS Disorders

    Products forSYNDROME) (DRAVET the TreatmentPhase of CENTRAL 3 Ready Phase NERVOUS 3 Initiated SYSTEM January (CNS) 2016Disorders 3 Late Stage Development Opportunities ONCE-MONTHLY ZX008 (low-dose fenfluramine) EPILEPSY SCHIZOPHRENIA

  4. Slide 4: ZX008 Opportunity in Dravet Syndrome

    ZX008 and E.U.Dravet Asia-Pacific Syndrome Partnering ZX008 Opportunity Global Ownership 4 Orphan Drug Designation in U.S. and E.U. IND Approved Dec. 2015; Phase 3 Initiation Jan. 2016 Fast Track Designation Intend to Commercialize Directly in U.S.

  5. Slide 5: History of Fenfluramine in Epilepsy

    History Dev. syncopes (Belgium) frequency; adjunctive Autism Epilepsia ofand 2016 Fenfluramine 5treatment 7Add seizure Disorders self-induced (doi: on therapy free, 10.1111/epi.13407) with 1987; in4low photosensitive Refractory seizure of17: dose fenfluramine 391-406 frequency fenfluramine Epilepsy

  6. Slide 6: Dravet Syndrome

    Dravet Syndrome comorbidities epilepsies blockers (e.g., Polypharmacy ?carbamazepine, ADHD, Intractable, behavior, is standard Severe oxcarbazepine, crouch of Epilepsy care gaitbut Recent lamotrigine) Which no effective, incidence Begins make long-term in study Infancy seizures 1/15,700 treatment Ge

  7. Slide 7: Low Dose Fenfluramine: Long Term Efficacy and Safety

    Low 12 Epilepsia for Dravet entire Dose5(2016) syndrome Fenfluramine: years;10 4/10 patients patients, patients Long from age Term seizure 92012 months Efficacy free publication for to and 13 at years least Safety still2(11 on years infenfluramine with Treating Overall confirmatory Dravet Safety the

  8. Slide 8: Evidence of Fenfluramine Effect in Zebrafish Model

    Evidence convulsive tance (Control) 8000of -/-seizure-like diFenfluramine (FA) s +/+Sourbron, (Con) behavior, ve Activity Schneider ents loss 6000 in Zebrafish ofet +/+ posture, al.(FA) Serotonergic Mutant m repetitive lati move Model Modulation jerking 4000 of Dravet cumu andasa myoclonic Effective

  9. Slide 9: Prospective Observational Study

    Prospective common Study the seizures hypertension 3-month Visits over AED?s Study Full baseline Schoonjans the at clinical entire of baseline: aperiod New study examination, et al Cohort Results valproate period, International of Rapid which Patients (100%), adverse and Child ranged effects, Confir

  10. Slide 10: ZX008 Clinical Program in Dravet Syndrome

    ZX0081502, 1501, therapy poor-responders Clinical to stiripentol 1503) Program designed PKregimen studies intoDravet maintain in ? Healthy children Syndrome EUadult 2-18 orphan volunteer, Safety years exclusivity (Study andand Efficacy 1504) pediatric and support Meets ? TwoDravet anticipated double

  11. Slide 11: Design of Phase 3 Safety and Efficacy Studies

    Design of Phase1:1:1 Randomization 11 3 Safety Titration and Efficacy 0.2 mg/kg/d Studies Placebo 6 WEEKS Two Identical 12 WEEKS Placebo BASELINE Controlled TREATMENT Maximum Long OBSERVATION Term StudiesZX008 Daily Dose 0.8 mg/kg/d of Open2 Label N = 105 US/Canada: week ZX008 ZX008-1501 Open Label

  12. Slide 12: Key Assessments

    Key Assessments convulsive mg/kg/day Doppler echocardiograms vs. seizure Placebo EFFICACY frequency is the ? 12-lead primary Longest Analyses electrocardiogram outcome convulsive for ZX008 measure seizure-free 0.8 12 mg/kg/day SAFETYinterval Adverse vs. Placebo, Clinical events global andLaboratory

  13. Slide 13: ZX008 Phase 3 Status

    ZX0083Phase University Phase Results sites 3 Status slower Now Anticipated Study than planned 1501inStudy Q2 ? Activation ?17 1502 Regulatory Initiated of newin Submissions sites January will bolster 2016 on 56% Track enrollment offor study H2 Initiated ?17 sites13 currently in Juneopen 2016with 47%

  14. Slide 14: ZX008 Market Research: Physician Perspectives

    ZX008 clinical mechanism grail Recommend game Market performance changer ofRecommend action Research: for is compared this demonstrated Physician 10 syndrome? Suggest to other Perspectives in 1?Not AEDs aAlarger USSuggest Awareness Neurologist patient Majority 0 0sample 2 of 4of ZX008: 6the physicia

  15. Slide 15: Establishing Patient Registry and Cardiac Monitoring

    Establishing Use Patient (14/447,369) of Fenfluramine Registry Product 15 and Cardiac in Protection Dravet Monitoring Syndrome ORPHAN Difficult and DRUGElements to STATUS Circumvent of a Provides Future andREMS Expensive 10 Years Program oftoMarket Replicate Ongoing Exclusivity (1) Preclinical Metho

  16. Slide 16: Exploring Use in Other Refractory Pediatric Epilepsy Conditions

    Exploring Plan to Evaluate The Usein 2H of ZX008 2016 Started In Other March Refractory 2016 (Phase Orphan2 Pediatric IIS) 16 Epilepsy Conditions Other Refractory Orphan Lennox Gastaut Pediatric Syndrome Epilepsy Conditions Investigator Initiated Study (Phase 2 IIS)

  17. Slide 17: ZX008 Milestones

    ZX008 Milestones Initiated ScientificStudy Exhibit (IIS) Room 2016 for Lennox-Gastaut ?Milestones DecemberCompleted ?16syndrome Phase to 3 Dravet Date Expected Initiated syndrome Upcoming U.S. data Phase Milestones ? Q23 ?17 trialZX008 (Study Interim Dravet 1501) results for syndrome from Dravet on-

  18. Slide 18: RELDAY: Once-Monthly Antipsychotic for Schizophrenia

    PHASE 3 READY Schizophrenia Proprietary Subcutaneous Once-Monthly Antipsychotic Highly Differentiated Profile Worldwide Rights Search Ongoing for Development and Commercialization Partner 18

  19. Slide 19: RELDAY Differentiated Profile

    RELDAY complicated need for reconstitution Has loading a Differentiated dose prior regimens to LAI use Intellectual Initiation Profile A Proven, dose Property identical Effective issued to maintenance and and pending Safe Molecule dose patents Once-monthly for through the Treatment at least dosing 2

  20. Slide 20: Financial Highlights

    Financial capital respectively advance Highlights 20 from Cash Endo(as International of 6-30-16)(2) $128M Fully Debt diluted (1)shares $20Minclude (as of 6-30-16) options toCommon purchaseShares 3.3 million Outstanding shares and (as of warrants 6-30-16) to 24.8 purchase M Fully 2.0 million Diluteds

  21. Slide 21: Promising Pipeline

    NASDAQ: PROMISING PIPELINE PHASE 3 PROGRAM INITIATED FOR ZX008 FULLY FUNDED CLINICAL PROGRAMS SIGNIFICANT NEAR-TERM MILESTONES EXPERIENCED TEAM IN PLACE

Zogenix — Investor Presentation (September 2016) on 6ix